Icosavax Inc

NASDAQ:ICVX   3:59:55 PM EDT
8.02
-0.75 (-8.55%)
Regulatory, Other Pre-Announcement

Icosavax Announces Positive Topline Interim Phase 1/1B Results For VLP Vaccine Candidate IVX-121 Against Rsv

Published: 06/28/2022 21:33 GMT
Icosavax Inc (ICVX) - Icosavax Announces Positive Topline Interim Phase 1/1b Results for Vlp Vaccine Candidate Ivx-121 Against Rsv.
Icosavax - Ivx-121 Showed Robust Immunologic Response to Rsv, With Comparable Gmt Levels Achieved at Day 28 in Both Young and Older Adult Groups.
Icosavax Inc - Ivx-121 Was Generally Well Tolerated With No Vaccine-related Saes.
Icosavax Inc - Plans to File an Ind Submission and Initiate a Phase 1 Trial for Ivx-a12, a Combination Bivalent Rsv + Hmpv Vlp Candidate, in 2h 2022.